Reported Earlier, Scilex Secures 5-Year Term Of $100M In Royalty-Based Financing For Non-Opioid Pain Management Expansion
Reported Earlier, Scilex Secures 5-Year Term Of $100M In Royalty-Based Financing For Non-Opioid Pain Management Expansion
早前報道，Scilex爲非阿片類疼痛管理擴展獲得了1億美元、基於版稅的融資期限爲5年。
The Company intends to use the funds to repay the outstanding amount of its existing senior secured loan provided by Oramed Pharmaceuticals Inc., which is approximately $85 million. The Company intends to use the rest of the funds raised, which is estimated to be $15 million, for general corporate purposes.
公司擬使用所有基金類型償還Oramed Pharmaceuticals Inc.提供的未償還資金，約8500萬美元。公司擬將剩餘籌集資金，預計約1500萬美元，用於一般企業用途。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。